Prevalence of TERT Promoter Mutations in Thai Patients with CNS WHO Grade 2 Meningiomas
Article Sidebar
Main Article Content
Abstract
OBJECTIVES: To determine the prevalence of telomerase reverse transcriptase (TERT) promoter mutations in Thai patients with atypical meningiomas and assess associations with clinical and histopathological features.
MATERIALS AND METHODS: A retrospective review was conducted. Demographic, clinical, and histopathological data were collected. TERT promoter mutations were identified and analyzed for associations with features such as chordoid or clear cell variants, mitosis ≥ 4, brain invasion, necrosis, and hypercellularity.
RESULTS: The cohort comprised 92 patients, 29 males and 63 females (median age 58). TERT promoter mutations were present in 5.43% of cases, most commonly C250T (60% of mutated cases). No significant associations were found between the mutation status and the assessed pathological features.
CONCLUSION: TERT promoter mutations were detected in a small proportion of Thai WHO Grade 2 meningiomas. While no significant correlations with pathological features were observed, these mutations may contribute to tumor biology, warranting further study on their prognostic and therapeutic relevance.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
WHO Classification of Tumours Editorial Board. Central nervous system tumours. In: WHO classification of tumours. 5th ed. Vol. 6. Lyon: International Agency for Research on Cancer; 2021. Available from: https://tumourclassification.iarc.who.int/chaptercontent/45/91.
Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21(Suppl 5):v1–100. doi:10.1093/neuonc/noz150.
Aghi MK, Carter BS, Cosgrove GR, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery. 2009;64(1):56–60. doi:10.1227/01.NEU.0000330399.55586.63.
Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077–80. doi:10.1126/science.1233009.
Williams SR, Juratli TA, Castro BA, et al. Genomic analysis of posterior fossa meningioma demonstrates frequent AKT1 E17K mutations in foramen magnum meningiomas. J Neurol Surg B Skull Base. 2019;80(6):562–7. doi:10.1055/s-0038-1676821.
Strickland MR, Gill CM, Nayyar N, et al. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. J Neurosurg. 2017;127(2):438–44. doi:10.3171/2016.8.JNS161076.
Abedalthagafi M, Bi WL, Aizer AA, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016;18(5):649–55. doi:10.1093/neuonc/nov316.
Sahm F, Bissel J, Koelsche C, et al. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol. 2013;126(5):757–62. doi:10.1007/s00401-013-1187-5.
Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45(3):285–9. doi:10.1038/ng.2526.
Sahm F, Schrimpf D, Olar A, et al. TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst.2016;108(5):djv377. doi:10.1093/jnci/djv377.
Qu Y, Shi L, Wang D, et al. Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers. Int J Cancer. 2014;134(12):2993–4. doi:10.1002/ijc.28633.
Nadeem M, Sravya P, Beniwal M, et al. Clinicopathological correlation of TERT (telomerase reverse transcriptase promoter) mutation in meningiomas. Neurol India. 2025;73(1):64–69. doi:10.4103/neurol-india.Neurol-India-D-23-00146.
Koelsche C, Sahm F, Capper D, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013;126:907–15. doi:10.1007/s00401-013-1195-5.
Biczok A, Kraus T. P12.03 Prognostic value of TERT promoter mutation in aggressive meningiomas. Neuro Oncol.2017;19(Suppl 3):iii95. doi:10.1093/neuonc/nox036.361.
Spiegl-Kreinecker S, Lötsch D, Neumayer K, et al. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol. 2018;20(12):1584–93. doi:10.1093/neuonc/noy104.
Sievers P, Hielscher T, Schrimpf D, et al. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol. 2020;140(3):409–13. doi:10.1007/s00401-020-02188-w.
Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science.2013;339(6122):959–61. doi:10.1126/science.1230062.
Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science.2013;339(6122):957–9. doi:10.1126/science.1229259
